Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alzamend Neuro, Inc., a Delaware corporation and emerging growth company, on July 9, 2025. The report addresses a corporate governance action regarding the company's capital structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statement data.
Material Changes
- Elimination of Series A Preferred Stock: On July 9, 2025, the Company filed a Certificate of Elimination with the Delaware Secretary of State.
- Effective Date: The elimination of the Series A convertible preferred stock from the Company's Certificate of Incorporation was effective immediately upon filing.
- Impact: All matters set forth in the Certificate of Designations for the Series A Preferred Stock have been removed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly procedural regarding the amendment to the Articles of Incorporation.
Investor Verification Checklist
- Verify the status of the Series A convertible preferred stock in the company's latest 10-K or 10-Q to confirm the conversion or redemption history leading to this elimination.
- Review the attached Exhibit 3.1 (Certificate of Elimination) for specific details on the number of shares eliminated.
- Confirm if this action impacts the company's weighted average shares outstanding or potential dilution from future conversions.